Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial.

Katz MH, Merchant NB, Brower S, Branda M, Posner MC, William Traverso L, Abrams RA, Picozzi VJ, Pisters PW, American College of Surgeons Oncology Group
Ann Surg Oncol. 2011 18 (2): 337-44

PMID: 20811779 · PMCID: PMC3922125 · DOI:10.1245/s10434-010-1282-y

MeSH Terms (13)

Adenocarcinoma Antineoplastic Agents Chemotherapy, Adjuvant Combined Modality Therapy Humans Multicenter Studies as Topic Neoplasm Recurrence, Local Neoplasm Staging Pancreatic Neoplasms Pancreaticoduodenectomy Reference Standards Survival Rate Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: